<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="128129">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01434186</url>
  </required_header>
  <id_info>
    <org_study_id>CV181-147</org_study_id>
    <secondary_id>2010-024568-16</secondary_id>
    <nct_id>NCT01434186</nct_id>
  </id_info>
  <brief_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy, safety, tolerability, of Saxagliptin (BMS-477118) in combination
      with Metformin in pediatric patients with type 2 diabetes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy
      and Safety of Saxagliptin (BMS-477118) in Combination with Metformin IR or Metformin XR in
      Pediatric Patients with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin
      Alone or in Combination with Baseline Insulin Therapy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in Glycosylated hemoglobin (HbA1c) in the short term treatment period</measure>
    <time_frame>Baseline and upto Week 16 (or the last post-baseline measurement prior to Week 16, if no Week 16 assessment is available)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in 2-hour Postprandial Glucose (PPG) Area under the curve (AUC) in the short term treatment period</measure>
    <time_frame>Baseline and upto Week 16 (or the last post-baseline measurement prior to Week 16, if no Week 16 assessment is available)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in FPG (Fasting plasma glucose) in the short term treatment period</measure>
    <time_frame>Baseline and upto Week 16 (or the last post-baseline measurement prior to Week 16, if no Week 16 assessment is available)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects with HbA1c &lt; 7% in the short term treatment period</measure>
    <time_frame>At Week 16 (or the last post-baseline measurement prior to Week 16, if no Week 16 assessment is available)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Arm 1: Saxagliptin +Metformin XR/IR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight) Metformin XR/IR 1000 mg-2000 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Placebo +Metformin XR/IR</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching saxagliptin 0 mg Metformin XR/IR 1000 mg - 2000 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching with Saxagliptin</intervention_name>
    <description>Tablet, Oral, 0.0 mg, Daily, Day 1 through week 52</description>
    <arm_group_label>Arm 2: Placebo +Metformin XR/IR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin IR</intervention_name>
    <description>Tablet, Oral, 1000 mg -2000 mg, Daily , Day 1 through week 52</description>
    <arm_group_label>Arm 1: Saxagliptin +Metformin XR/IR</arm_group_label>
    <arm_group_label>Arm 2: Placebo +Metformin XR/IR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin XR</intervention_name>
    <description>Tablet, Oral, 1000 mg -2000 mg, Daily, Day 1 through week 52</description>
    <arm_group_label>Arm 1: Saxagliptin +Metformin XR/IR</arm_group_label>
    <arm_group_label>Arm 2: Placebo +Metformin XR/IR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin</intervention_name>
    <description>Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight)</description>
    <arm_group_label>Arm 1: Saxagliptin +Metformin XR/IR</arm_group_label>
    <other_name>BMS-477118</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients eligible if 10 years of age, up to 17 years and 30 weeks of
             age at the time of screening

          -  Previously diagnosed as having type 2 diabetes

          -  HbA1c ≥7.0% and ≤10.5%

          -  Body weight ≥ 30 kg

          -  Stable dose of metformin (≥ 1000mg - ≤ 2000mg) for a minimum of 2 months

          -  Women must have a negative serum or urine pregnancy test

          -  Women must not be breastfeeding

        Exclusion Criteria:

          -  Current use of anti-diabetic medications or use within the specified timeframe prior
             to screening (Exception: Metformin)

          -  Fasting plasma glucose (FPG) &gt; 255 mg/dL

          -  Diabetic ketoacidosis (DKA) within 6 months of study entry

          -  Abnormal renal function

          -  Active liver disease

          -  Anemia

          -  An abnormal Thyroid Stimulating Hormone (TSH)

          -  Creatinine kinase (CK) ≥ 3X ULN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Meridas</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Veracruz</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>India</country>
    <country>Mexico</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Turkey</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 19, 2017</lastchanged_date>
  <firstreceived_date>September 13, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Saxagliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
